Alzheimer's Drug Discovery Foundation

For 25 years, the ADDF has supported the work of Dr. Frank Longo, including an early investment in PharmatrophiX. That long-term support is reflected in the continued progress of LM11A-31, which Dr. Longo recently discussed on @CNBC's Squawk Box. cnbc.com/video/2026/07/…

“Subcutaneous approval is an important step toward the kind of scalable care model #Alzheimers will need as the field moves from single-drug treatment toward combination therapies,” said Dr. Laura Nisenbaum of @TheADDF. #lecanemab #leqembi vist.ly/5bnzw

New phase 2 data presented by @Biogen today at #AAIC2026 show diranersen (#BIIB080) is the first tau-targeting drug to demonstrate a robust biomarker effect and clinical signal. Read more: bit.ly/4gxy6cF

The ADDF’s Diagnostics Accelerator and @MichaelJFoxOrg are joining forces to accelerate the development of scalable, minimally invasive biomarkers for co-pathologies found across Alzheimer’s and Parkinson’s. Learn more: bit.ly/4h7EmYL

“#Alzheimer’s is not driven by a single mechanism. It involves amyloid, tau, and novel pathways like #inflammation, vascular health and metabolism,” Dr. Laura Nisenbaum of @TheADDF said about what she expects to see at #AAIC26. @alzassociation vist.ly/5ax75

New in Solving Alzheimer's: the ADDF's Laura Nisenbaum explores how Alzheimer's diagnosis is evolving. From FDA-cleared blood tests to AI-powered tools, these innovations are making detection more accessible, scalable, and precise. bit.ly/4p1rB3V

Friends, I'm running the @NYCMarathon this fall for @TheADDF for the 12th time. I'd love your support as I run to help find better treatment and a cure for Alzheimer's! 🏃‍♂️🏃‍♂️🏃‍♂️ #TeamADDF More info here: fundraisers.nyrr.org/ernest-scheyde…

Could AI detect Alzheimer's through speech? Changes in word choice and speech patterns can emerge years before symptoms appear. A new paper in Alzheimer's & Dementia explores how AI could turn these signals into digital markers for cognitive decline. bit.ly/4vlZdvJ

Today, the ADDF announced that Co-Founder and Chief Science Officer Dr. Howard Fillit will retire and transition to an emeritus role. Please join us in recognizing Dr. Fillit’s extraordinary contributions to the ADDF and the Alzheimer’s field. bit.ly/4eu6LoT

FDA-approved blood tests for Alzheimer's are here. Through DxA 3.0, we aim to advance biomarkers that detect tau pathology and support staging and prognosis, helping clinicians and patients better understand disease progression. @WSJ wsj.com/health/wellnes…

The ADDF and @CTADconference are partnering to advance emerging biotech innovation at CTAD 2026 and build momentum toward a new era of Alzheimer's treatments. Learn more about the CTAD 2026 Biotech Showcase and opportunities for participating companies. 🔗bit.ly/3QoMkSk

A review in @JAMAPsych explores 25 years of evidence on lithium as a potential disease-modifying therapy for Alzheimer's. Identifying therapies that target the underlying biology may help accelerate treatments that delay, slow, or prevent the disease. bit.ly/4v1VKSV

There's still time to apply for the 2027 ADDF-Harrington Scholar Award. This joint RFP is designed to accelerate innovative research that could treat, prevent, slow, or reverse Alzheimer’s and related dementias. Letters of intent are due June 8. bit.ly/2rEQkiv

The ADDF's Aaron Burstein shares with the @washingtonpost how findings from Evoke/Evoke+ trials are helping researchers better understand biological pathways linked to Alzheimer's and future prevention strategies. washingtonpost.com/health/2026/05…

A recent @Barrons article featured insights from the ADDF's Laura Nisenbaum, who noted that Biogen's #CELIA results suggest "targeting tau can have both biological and clinical effects, which is exactly the kind of signal the field has been working on." barrons.com/articles/bioge…

Join the ADDF’s CEO Isobel Coleman for a live conversation about the organization’s next chapter, the momentum in Alzheimer’s research, and the potential for AI to accelerate innovation. 📅 June 3, 2026 🕧 12:30 pm ET Register here: bit.ly/4nR4nNh

@Roche received CE Mark approval for the Elecsys pTau217 blood test, developed with @EliLillyandCo & powered by ADDF-funded @AlZpath’s pTau217 antibody. The approval marks another important step toward broader access to scalable Alzheimer’s diagnostics. reut.rs/4dBdopf

New Phase 2 results from @biogen's CELIA study of #BIIB080 mark an encouraging step toward targeting Alzheimer’s beyond amyloid, reinforcing #tau as a promising target and highlighting momentum toward next-generation therapies. bit.ly/438aL9k

Today, #Fujirebio received CE Marking in the European Union for its ADDF-funded pTau217 test, following FDA approval in the U.S. The milestone reflects growing global momentum behind scalable, validated biomarkers and a broader shift in the field. bit.ly/4uftuMf

The 16th annual Great Ladies Luncheon raised a record-breaking $850,000 for Alzheimer's research at The Ritz-Carlton DC. Read the full story on The Washington Lobbyist: thewashingtonlobbyist.com/great-ladies-l… #DCFashionEvents #ADDFLadiesLuncheon @TheADDF #GreatLadiesLuncheon #BrainHealth